Literature DB >> 7903260

Major histocompatibility complex-encoded antigen processing gene polymorphism in IDDM.

P M van Endert1, R S Liblau, S D Patel, L Fugger, T Lopez, F Pociot, J Nerup, H O McDevitt.   

Abstract

Susceptibility to insulin-dependent diabetes mellitus (IDDM) is greatly influenced by polymorphisms in the genes of the class II region of the human leukocyte antigen (HLA) complex. The complexity of this genetic association and the lack of a direct proof of involvement of HLA class II genes in human IDDM have continued to support speculation on a possible role of genes encoded in the close vicinity of these loci in IDDM. Because the recently discovered transporter associated with antigen processing (TAP) and large multifunctional protease (LMP) genes are encoded in the HLA class II region and are implicated in the processing of antigenic proteins for presentation by HLA class I molecules, they are additional candidates for a role in IDDM pathogenesis. We have analyzed genomic and coding sequence polymorphisms in the LMP2, TAP1, and TAP2 genes of 77 Danish IDDM patients and 102 control subjects. Although patients and control subjects did not differ in TAP1 and LMP2 alleles, we found a striking absence of the TAP2 allele B (long form) in IDDM patients. An analysis of the TAP2 alleles in individual DR types, however, revealed that this phenomenon is likely to be caused by linkage disequilibrium between the two loci. Thus, polymorphisms in the TAP and LMP genes are unlikely to be associated with IDDM.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7903260     DOI: 10.2337/diab.43.1.110

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  12 in total

Review 1.  Genetic predisposition to IDDM.

Authors:  S Caillat-Zucman; J F Bach
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

2.  The relationship of lmp2 and DR3 genes with susceptibility to type I diabetes mellitus in south China Han population.

Authors:  He-Li Ding; Hua Cheng; Zu-Zhi Fu; Qing-Li Deng; Li YanLAST_NAME> Tang Yan; Tang Yan
Journal:  World J Gastroenterol       Date:  2000-02       Impact factor: 5.742

3.  Defective major histocompatibility complex class I expression on lymphoid cells in autoimmunity.

Authors:  J Piniés; L Castaño; P Colman
Journal:  J Endocrinol Invest       Date:  1994 Jul-Aug       Impact factor: 4.256

Review 4.  Molecular mechanisms of class I major histocompatibility complex antigen processing and presentation.

Authors:  Y Yang; P Sempé; P A Peterson
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

Review 5.  Superantigens in insulin-dependent diabetes mellitus.

Authors:  P Luppi; M Trucco
Journal:  Springer Semin Immunopathol       Date:  1996

Review 6.  Spotlight on TAP and its vital role in antigen presentation and cross-presentation.

Authors:  Ian Mantel; Barzan A Sadiq; J Magarian Blander
Journal:  Mol Immunol       Date:  2021-12-29       Impact factor: 4.174

7.  Genetic susceptibility to type 1 diabetes in the intracellular pathway of antigen processing - a subject review and cross-study comparison.

Authors:  Charles Sia; Michael Weinem
Journal:  Rev Diabet Stud       Date:  2005-05-10

8.  Myelin oligodendrocyte glycoprotein peptide-induced experimental allergic encephalomyelitis and T cell responses are unaffected by immunoproteasome deficiency.

Authors:  Ricardo F Frausto; Stephen J Crocker; Boreth Eam; Jason K Whitmire; J Lindsay Whitton
Journal:  J Neuroimmunol       Date:  2007-10-26       Impact factor: 3.478

9.  Association of LMP2 and LMP7 genes within the major histocompatibility complex with insulin-dependent diabetes mellitus: population and family studies.

Authors:  G Y Deng; A Muir; N K Maclaren; J X She
Journal:  Am J Hum Genet       Date:  1995-02       Impact factor: 11.025

10.  TAP1 and TAP2 gene polymorphisms in Korean patients with allergic rhinitis.

Authors:  Kyung Rae Kim; Seok Hyun Cho; Suk Joo Choi; Jin Hyeok Jeong; Seung Hwan Lee; Chul Won Park; Kyung Tae
Journal:  J Korean Med Sci       Date:  2007-10       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.